StockMarketWire.com - Stem-cell research and development company ReNeuron Group plc has signed a manufacturing agreement with NHS Blood and Transplant for its next-generation stem cell product CTXcryo.

ReNeuron said NHSBT will use its state-of-the-art, accredited cell manufacturing facilities to develop and manufacture CTXcryo for pre-clinical development work and eventual clinical use in the company's ReN009 programme for peripheral arterial disease.

The CTXcryo product is a second-generation formulation of ReNeuron's lead CTX stem cell line, the basis of its ReN001 therapy for stroke, currently in early clinical development.

It said the arrangements will complement its existing contract manufacturing arrangements with Angel Biotechnology in Scotland.

CEO Michael Hunt said, 'Although further optimisation work remains to be done, the transfer of the production process for the CTXcryo cells to NHSBT represents an important milestone in our product development and cell manufacturing strategy and is a further step towards realising our vision to develop safe, effective and readily scalable stem cell-based therapeutics for wide-scale patient use in significant disease conditions.'

NHSBT is the UK's major provider of human tissue, stem cells and organs for transplant.




At 9:16am: [LON:RENE] share price was +0.03p at 5.85p



Story provided by StockMarketWire.com